HLS Therapeutics Inc. (OTCMKTS:HLTRF) Stock Short Interest Drops 93.5%

HLS Therapeutics Inc. (OTCMKTS:HLTRF) was the target of a significant decline in short interest during the month of September. As of September 30th, there was short interest totaling 100 shares, a decline of 93.5% from the September 15th total of 1,546 shares. Based on an average daily trading volume, of 927 shares, the days-to-cover ratio is presently 0.1 days.

HLS Therapeutics Price Performance

OTCMKTS:HLTRF remained flat at $2.75 on Friday. HLS Therapeutics has a 1 year low of $2.64 and a 1 year high of $4.02. The firm’s fifty day moving average is $2.78 and its 200-day moving average is $3.03.

Wall Street Analysts Forecast Growth

Separately, Raymond James Financial raised HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating. Based on data from MarketBeat, HLS Therapeutics presently has a consensus rating of “Strong Buy”.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company focused on acquiring, developing and commercializing medicines in Canada and the United States. The company concentrates on products that address significant medical needs, with an emphasis on central nervous system and cardiovascular therapies.

HLS has commercialized branded prescription medicines and specialty products through partnerships, licensing arrangements and acquired product rights. Its portfolio has included Clozaril (clozapine), a treatment used in schizophrenia, as well as other therapies marketed through specialty-care and hospital channels.